India, June 7 -- Eli Lilly and Company (LLY) announced new results showing that women with obesity or overweight who took the highest dose of Foundayo achieved significant weight loss at every stage of menopause. These findings are based on post-hoc analyses of more than 1,500 female participants in the ATTAIN-1 and ATTAIN-2 clinical trials.
In the ATTAIN-1 study, women in perimenopause lost up to 30.4 lbs (14.4%), while those in post-menopause lost up to 28.2 lbs (14.1%). These results highlight the effectiveness of Foundayo in supporting weight management during different phases of menopause.
In ATTAIN-2, women taking Foundayo experienced significant weight loss across all stages of menopause, even when living with type 2 diabetes - a c...